Utilizing Inflammatory Biomarkers to Assess the Activity of a Novel Therapeutic in Frontotemporal Dementia Patients with Granulin Mutation

Time: 12:15 pm
day: Day One


  • Examining biomarkers specifically for frontotemporal dementia, a rapidly progressive form of dementia, to address the gap in therapeutic development for neurodevelopmental disease, as there are currently none approved for this condition
  • Leveraging biomarkers to evaluate hallmarks of frontotemporal dementia pathophysiology to aid drug development
  • Implementing a biomarker strategy in a clinical study to assess treatment impact in frontotemporal patients with a granulin mutation